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Background: Once-daily combination treatment is an attractive maintenance therapy for
COPD. However, the dose of inhaled corticosteroid to use in a once-daily combination is un-
known. We compared two strengths of fluticasone furoate (FF) plus vilanterol (VI), the same
strengths of the individual components, and placebo.
Methods: Multicentre, randomised, 24-week, double-blind, placebo-controlled, parallel-group
study in stable, moderate-to-severe COPD subjects (N Z 1224). Subjects were randomised to
FF/VI (200/25 mg; 100/25 mg), FF (200 mg; 100 mg), VI 25 mg, or placebo, once daily in the morn-
ing. Co-primary efficacy endpoints; 0e4 h weighted mean (wm) FEV1 on day 168, and change
from baseline in trough (23e24 h post-dose) FEV1 on day 169. The primary safety objective was
adverse events (AEs).
Results: There was a statistically significant (p < 0.001) increase in wm FEV1 (209 ml) and
trough FEV1 (131 ml) for FF/VI 200/25 mg vs. placebo; similar changes were seen for FF/VI
100/25 mg vs. placebo. Whereas the difference between FF/VI 200/25 mg and VI 25 mg in change
from baseline trough FEV1 (32 ml) was not statistically significant (p Z 0.224), the difference
between FF/VI 200/25 mg and FF 200 mg for wm FEV1 (168 ml) was significantly differentf Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA. Tel.: þ1 734 936
ich.edu (F.J. Martinez).
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cess under CC BY-NC-ND license.
FF/VI 100/25 mg, 200/25 mg in COPD 551(p < 0.001). VI 25 mg significantly improved wm and trough FEV1 vs. placebo (209 ml and
131 ml, respectively). No increase was seen in on-treatment AEs or serious AEs (SAEs), with ac-
tive therapy vs. placebo.
Conclusions: FF/VI provides rapid and significant sustained improvement in FEV1 in subjects
with moderate-to-severe COPD, which was not influenced by the dose of FF. These data sug-
gest that FF/VI may offer clinical efficacy in COPD and warrants additional study.
GSK study number: HZC112207.
ClinicalTrials.gov: NCT01054885.
ª 2013 Elsevier Ltd.Open access under CC BY-NC-ND license.Introduction
The efficacy and safety of combination inhaled cortico-
steroid (ICS) and long-acting b2-agonist (LABA) therapy is
well established1e4 for the maintenance treatment of
moderate-to-severe chronic obstructive pulmonary disease
(COPD), and this approach has been recognised by evidence
based guidelines.5e8 The most recent revision of the in-
ternational GOLD statement further codifies such therapy
by recommending that combination inhaled corticosteroid
(ICS)/LABA therapy can be considered first-line in COPD
patients at high risk for acute exacerbations.5 There is
increasing interest in moving to once-daily dosing for res-
piratory medications. One long-acting muscarinic antago-
nist (LAMA), tiotropium,9 offers once-daily dosing, as does
the phosphodiesterase-4 inhibitor roflumilast,10 and the
LABA indacaterol.11 However, to date all ICS/LABA combi-
nation therapies require twice-daily dosing. Twice-daily
dosing may result in lower adherence and greater COPD
costs than once-daily dosing.12
Vilanterol (VI) is a LABA that can provide effective once-
daily dosing in COPD at a dose of 25 mg.13 Fluticasone
furoate (FF) is a novel ICS whose effects as a monotherapy
have not been investigated previously in COPD. In asthma
the efficacy of FF as a once-daily therapy has been estab-
lished in a series of studies investigating doses between
12.5 mg and 800 mg.14e16 Also in asthma, FF at a dose of
100 mg once daily exhibited similar efficacy to fluticasone
propionate at a dose of 250 mg twice daily over 24 weeks.17
In developing the combination FF/VI for clinical use, novel
dose ranging of the ICS component of the combination was
conducted in multiple phase III studies. In this report we
describe the findings of one of the studies, which investigated
the effect of FF at doses of 100 mg and 200 mg added to VI. The
objectives of our study were to assess the bronchodilatory
effect of FF/VI using twomeasures of lung function (weighted
mean forced expiratory volume in 1 s [FEV1] over the first 4 h
post-dose, and troughFEV1 assessedw24hafter thefinal dose
on day 168) to determine the effect of addition of FF to VI on
those lung function outcomes; to assess whether any dose
effect was observed with FF; to confirm the once-daily bron-
chodilatory capacity of VI; and to determine the safety and
tolerability of all active treatments.
Methods
A detailed description of all methods is provided in the
Online Supplement.Subjects and ethics
The study was conducted between October 2009 and March
2011 at study centres in eight countries (Czech Republic,
Germany, Japan, Poland, Romania, Russian Federation,
Ukraine, and the United States). Participating subjects had
a clinical diagnosis of COPD, an age 40 years, a smoking
history of 10 pack-years, a post-bronchodilator FEV1/
forced vital capacity (FVC) ratio of 0.70, a post-
bronchodilator FEV1 70% predicted (NHANES III) and
a score of 2 on the Modified Medical Research Council
Dyspnoea Scale (mMRC). No prior history of COPD exacer-
bations was required for subjects to be eligible to enter the
study. Reversibility to albuterol was assessed at the
screening visit; both reversible and non-reversible subjects
were eligible to enter the study.
Exclusion criteria included any respiratory disorder
other than COPD; lung volume reduction surgery within the
12 months of screening; acute worsening (subject-managed
corticosteroid or antibiotic treatment or physician pre-
scription) of COPD within 6 weeks of screening, or a hospi-
talisation for COPD in the 12 weeks, or a lower respiratory
tract infection that required the use of antibiotics in the 6
weeks before screening; the need for long-term oxygen
therapy or nocturnal oxygen therapy (12 h/day).
All subjects gave written informed consent and the
protocol was approved by the appropriate institutional re-
view boards and conducted in accordance with good clinical
practice guidelines and the Declaration of Helsinki.Study design and treatments
This was a 24-week, multicentre, randomised, stratified
(by smoking status), placebo-controlled, double-blind,
parallel-group study (Fig. E1; GlaxoSmithKline study
number HZC112207; ClinicalTrials.gov: NCT01054885).
Study subjects were stratified by smoking status (former
smoker Z not smoked for 6 months prior to the screening
visit). At visit 1 (screening), subjects entered a 2-week,
single-blind run-in period during which they received
placebo once daily in the morning via a dry powder inhaler
(DPI) that contains two strips (GlaxoSmithKline, London,
UK). The screening period was used to obtain a baseline
assessment of symptoms (breathlessness, cough, sputum
production and night-time awakenings requiring rescue
medication [albuterol/salbutamol], rescue medication use
and adherence to therapy). Eligible subjects were rando-
mised (1:1:1:1:1:1) to one of six double-blind treatments
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FF 200 mg, VI 25 mg (representing emitted doses of FF/VI
184/22 mg, FF/VI 92/22 mg, FF 184 mg, FF 92 mg and VI
22 mg), or placebo taken once daily in the morning using
a DPI. A central randomisation schedule was generated
using a validated computerised system (RandAll; Glax-
oSmithKline, London, UK) and subjects were randomised
using the Registration and Medication Ordering System
(RAMOS; GlaxoSmithKline, London, UK) to register the
subject, randomise the subject and receive medication
assignment information. Subjects withheld study medi-
cation on the morning of clinic visits and rescue medi-
cation for at least 4 h prior to and during clinic visits.
Albuterol (salbutamol) was allowed during the run-in and
treatment periods for use as symptom relief, as was
ipratropium bromide provided the dose was a stable dos-
ing regimen from the screening visit onward. Other per-
mitted and prohibited co-medications are provided in the
Online Supplement.
Efficacy measurements
The co-primary efficacy outcomes were the weighted mean
(wm) FEV1 (0e4 h post-dose) on day 168 to assess broncho-
dilation by FF/VI and VI (vs. placebo) and FF/VI vs. FF; and
the change from baseline in trough (23e24 h post-dose) FEV1
on day 169 to assess the 24 h effect of VI and to determine
the contribution of FF to lung function (i.e. FF/VI vs. VI). wm
FEV1 (0e4 h) is derived by calculating the AUC from FEV1
measured 5 min, 15 min, 30 min, 1, 2 and 4 h post-dose, and
then dividing the AUC by the time interval. The AUC is cal-
culated using the trapezoidal rule. It acts as a more robust
measure of post-dose lung function than peak FEV1.
Secondary efficacy endpoints were the Chronic Respi-
ratory Questionnaire Self-Administered Standardized (CRQ-
SAS) dyspnoea domain on day 168, peak FEV1 (0e4 h) on day
1 and time to 100 ml improvement from baseline in FEV1
on day 1 (0e4 h).
Other endpoints were the time to 12% improvement in
FEV1 over the first 4 h post-dose on day 1; weighted mean
FEV1 0e4 h post-dose on days 1, 14, 56, and 84; change from
baseline in trough FEV1 on treatment days 2, 7, 14, 28, 56,
84, 112, and 140; percentage of symptom-free 24-h periods;
percentage of rescue-free 24-h periods; symptom scores
(breathlessness scaled from 0 to 4, cough and sputum scores
scaled from 0 to 3, with 0 indicating no impairment); num-
ber of occasions of rescue albuterol used; percentage of
nights with no night-time awakenings requiring albuterol;
number of night-time awakenings requiring albuterol; mean
morning peak expiratory flow (AM PEF); and CRQ-SAS other
domains and total score.
Safety evaluation
Safety observations included the incidence of adverse
events (AEs), COPD exacerbations, and all pneumonias.
Exacerbations were defined as moderate (acute worsening
of COPD requiring systemic corticosteroids and/or antibi-
otics) or severe (requiring hospitalisation). In addition,
AEs of special interest were defined a priori as those
known to be associated with ICS and/or LABA therapy.Change from baseline in pulse rate, systolic blood pressure
(BP), diastolic BP, 12-lead electrocardiogram (ECG) as-
sessments (for heart rate and QTcF [QT interval corrected
using Friedericia’s formula]) and clinical chemistry and
haematology parameters (including glucose and potassium
levels) were also assessed. An oropharyngeal examination
was conducted at each treatment visit for all subjects,
and in two subsets of subjects either Holter reading as-
sessments (nZ 541) or 24-h urinary cortisol (UC) excretion
(n Z 406; UC population) were assessed. The Holter and
UC populations were recruited from selected sites to
reduce the total burden of assessments on individual pa-
tients and sites.
Spirometric measurements
Spirometry was performed using equipment that met or
exceeded the minimum performance recommendations of
the American Thoracic Society.18 Reference values were
those of NHANES III.19
Statistical analysis
Assuming a standard deviation (SD) of 210 ml derived from
prior studies of VI13 and significance at the two-sided 5%
level, a sample size of at least 146 evaluable subjects per
arm was required for 90% power to detect a 100 ml dif-
ference between VI or FF/VI and placebo for wm or trough
FEV1 and between FF/VI and FF for wm FEV1 and to detect
an 80 ml difference between FF/VI and VI, for trough FEV1.
To allow for a 27% withdrawal rate based on prior trial
experience (GlaxoSmithKline, Data on File), at least 200
subjects were to be randomised per arm (1200 were plan-
ned to be randomised in total).
The primary analyses were performed on the intent-to-
treat (ITT) population, which comprised all subjects rand-
omised to treatment and who had received at least one
dose of study medication. Change from baseline trough
FEV1 recorded on days 2, 7, 14, 28, 56, 84, 112, 140, 168,
and 169 was analysed using mixed models repeated mea-
sures (MMRM) with covariates of baseline FEV1, smoking
status (stratum), day, centre grouping, treatment, day by
baseline interaction and day by treatment interaction,
where day was nominal. wm FEV1 recorded on days 1, 14,
56, 84 and 168 was analysed similarly. The CRQ-SAS was
analysed using the same methodology as the co-primary
endpoints, except the covariate of baseline dyspnoea
score replaced that of baseline FEV1. Peak FEV1 was ana-
lysed using analysis of co-variance (ANCOVA) with cova-
riates of baseline, smoking status, centre grouping and
treatment.
This study included two co-primary endpoints and 6
treatment arms. As a consequence, there were 10 treat-
ment comparisons of primary interest. Even if there were
no differences between treatments then, by definition, 5%
of treatment comparisons might be expected to be signifi-
cant purely by chance. Hence, it was necessary to control
for this when designing the trial. A pre-defined testing hi-
erarchy was therefore employed (Fig. 1). Level 1 of the
hierarchy comprised six key comparisons of the co-primary
endpoints for VI 25 mg and FF/VI 200/25 mg, each of which
Figure 1 Statistical hierarchy. FEV1 Z forced expiratory
volume in 1 s, FF Z fluticasone furoate, VI Z vilanterol,
wm Z weighted mean.
FF/VI 100/25 mg, 200/25 mg in COPD 553was equally weighted. Significance with a p < 0.05 was
required for all of these comparisons to allow statistical
significance to be inferred for differences, with p < 0.05 for
co-primary endpoints for the FF/VI 100/25 mg strength.Figure 2 Consort diagram. FF Z fluticasone furoInferences could only be made for secondary endpoints if
primary endpoints were significant at the 5% level.Results
Subject characteristics
Of 1909 subjects screened, 1224 comprised the ITT popu-
lation. In total, 924 (75%) subjects completed the study;
subject disposition and reasons for discontinuation are
shown in Fig. 2. In total 683 subjects were excluded, 332 at
the screening stage and a further 351 during the run-in
period. The primary reason for exclusion at screening or
during run-in was that the subject did not meet the entry
(n Z 323) or continuation (n Z 246) criteria, respectively.
The principle reason for not meeting entry criteria was
severity of disease (n Z 283), while the principle reasons
for not meeting continuation criteria were abnormal Holter
(nZ 108) or ECG (nZ 75) findings. A summary of screening
demographics, lung function and dyspnoea is shown in
Table 1.
Efficacy: co-primary
Combination therapy with FF/VI 200/25 mg resulted in sig-
nificant increases in adjusted wm FEV1 (0e4 h) on day 168
of 209 ml (95% CI: 157, 261; p < 0.001) and adjusted mean
trough FEV1 on day 169 of 131 ml (95% CI: 80, 183;ate, ITT Z intention to treat, VI Z vilanterol.
Table 1 Subject characteristics.
Placebo
N Z 205
FF 100 mg
N Z 204
FF 200 mg
N Z 203
VI 25 mg
N Z 203
FF/VI 100/25 mg
N Z 204
FF/VI 200/25 mg
N Z 205
Age, yr (SD) 61.9 (8.14) 61.8 (8.28) 61.8 (9.02) 61.2 (8.62) 61.9 (8.79) 61.1 (8.58)
Male sex, n (%) 152 (74) 150 (74) 151 (74) 151 (74) 144 (71) 137 (67)
Race, n (%)
White 197 (96) 197 (97) 183 (90) 196 (97) 190 (93) 192 (94)
Asian 8 (4) 5 (2) 14 (7) 4 (2) 8 (4) 11 (5)
Other 0 2 (<1) 6 (3) 3 (1) 6 (3) 2 (<1)
Current smoker, n (%) 108 (53) 114 (56) 112 (55) 111 (55) 109 (53) 112 (55)
Smoking history,
pack-yr (SD)
45.7 (25.8) 39.8 (21.3) 43.5 (22.5) 42.0 (23.3) 42.8 (23.9) 41.5 (23.4)
COPD type, n (%)
Chronic bronchitis 133 (65) 152 (75) 137 (67) 140 (69) 143 (70) 138 (67)
Emphysema 126 (61) 118 (58) 129 (64) 113 (56) 109 (53) 129 (63)
Pre-study COPD therapy, n (%)
SABA 125 (61) 128 (63) 128 (63) 123 (61) 136 (67) 124 (60)
SAMA 76 (37) 61 (30) 61 (30) 72 (35) 67 (33) 77 (38)
LABA 77 (38) 64 (31) 66 (33) 81 (40) 74 (36) 66 (32)
LAMA 49 (24) 49 (24) 42 (21) 44 (22) 46 (23) 61 (30)
ICS 47 (23) 50 (25) 53 (26) 55 (27) 37 (18) 46 (22)
On-treatment non-COPD
medication, n (%)
151 (74) 150 (74) 149 (73) 151 (74) 150 (74) 142 (69)
Screening pre-BD
FEV1, l (SD)
1.349 (0.4512) 1.412 (0.4839) 1.304 (0.4870) 1.371 (0.4755) 1.357 (0.5188) 1.330 (0.5025)
Screening post-BD
FEV1, l (SD)
1.504 (0.4675) 1.532 (0.4814) 1.436 (0.4744) 1.519 (0.4719) 1.491 (0.5094) 1.458 (0.5117)
Screening % predicted
pre-BD FEV1, % (SD)
43.5 (13.00) 44.6 (12.98) 42.7 (12.72) 43.7 (12.85) 43.8 (13.81) 43.0 (13.01)
Screening % predicted
post-BD FEV1, % (SD)
48.3 (12.71) 48.4 (12.17) 47.1 (11.98) 48.5 (12.89) 48.1 (12.85) 47.1 (12.76)
Screening FEV1
reversibility, ml (SD)
153.1 (165.94) 128.9 (188.76) 130.0 (157.57) 143.7 (177.89) 134.9 (188.31) 113.3 (175.58)
Reversible at
screeninga n (%)
61 (30) 57 (29) 54 (27) 60 (30) 58 (29) 54 (27)
Screening mMRC
dyspnoea scale,
units (SD)
2.4 (0.55) 2.4 (0.54) 2.4 (0.54) 2.4 (0.51) 2.4 (0.52) 2.4 (0.50)
Moderate exacerbation in the year prior to screening, n (%)
0 166 (81) 156 (76) 140 (69) 152 (75) 154 (75) 152 (74)
1 39 (19) 48 (24) 63 (31) 51 (25) 50 (25) 53 (26)
Severe exacerbation in the year prior to screening, n (%)
0 185 (90) 186 (91) 180 (89) 186 (92) 180 (88) 185 (90)
1 20 (10) 18 (9) 23 (11) 17 (8) 24 (12) 20 (10)
Moderate exacerbation required oral/systemic corticosteroids and/or antibiotics but did not involve hospitalisation; severe exacer-
bation required hospitalisation; BDZ twice daily, COPDZ chronic obstructive pulmonary disorder, FEV1Z forced expiratory volume in
1 s, FFZ fluticasone furoate, ICSZ inhaled corticosteroid, LABAZ long-acting b2-agonist, LAMAZ long-acting muscarinic antagonist,
mMRC Z Modified Medical Research Council Dyspnoea Scale, SABA Z short-acting b2-agonist, SAMA Z short-acting muscarinic antag-
onist, SD Z standard deviation, VI Z vilanterol.
a Reversible to albuterol/salbutamol as defined by 12% and 200 ml improvement in FEV1 post-dose.
554 F.J. Martinez et al.p < 0.001), compared with placebo (Table 2). No significant
increase in adjusted mean trough FEV1 was observed for the
comparison of FF/VI 200/25 mg with VI 25 mg (32 ml, 95% CI:
e19, 83; p Z 0.224), while the comparison of FF/VI 200/
25 mg with FF 200 mg indicated a significant improvement
with the combination vs. the ICS alone for adjusted wm FEV1
(168 ml, 95% CI: 117, 219; p < 0.001) (Table 2). VI 25 mg
monotherapy significantly improved both lung functionparameters (wm and trough FEV1) by 185 ml (95% CI: 133,
237; p < 0.001) and 100 ml (95% CI: 48, 151; p < 0.001)
respectively, compared with placebo. Due to the pre-defined
statistical testing hierarchy no inference can be drawn for
comparisons of the 100/25 mg strength with placebo or its
components, as there was no significant difference in the
change in lung function between VI and the highest strength
of FF/VI. However the differences observed with FF/VI 100/
Table 2 Primary and secondary efficacy comparisons.
Comparisons wm FEV1
(0e4 h) day 168
Trough
FEV1 day 169
CRQ-SAS
dyspnoea day 168
Peak FEV1
a
day 1
VI vs. PBO 0.185* (0.133, 0.237) 0.100* (0.048, 0.151) 0.07 (0.14, 0.28) 0.147 (0.117, 0.177)
FF 200 comparisons
FF/VI 200/25 mg
vs. PBO
0.209* (0.157, 0.261) 0.131* (0.080, 0.183) 0.1 (0.12, 0.31) 0.141 (0.111, 0.171)
FF/VI 200/25 mg
vs. VI 25 mg
0.024 (0.027, 0.075) 0.032** (0.019, 0.083) 0.03 (0.18, 0.23) 0.006 (0.036, 0.024)
FF/VI 200/25 mg
vs. FF 200 mg
0.168* (0.117, 0.219) 0.123 (0.072, 0.174) 0.1 (0.11, 0.31) 0.134 (0.104, 0.164)
FF 200 mg vs. PBO 0.041 (0.011, 0.093) 0.008 (0.044, 0.060) 0.01 (0.22, 0.21) 0.007 (0.023, 0.037)
FF 100 comparisons
FF/VI 100/25 mg
vs. PBO
0.214 (0.161, 0.266) 0.144 (0.091, 0.197) 0.24 (0.02, 0.46) 0.152 (0.122, 0.182)
FF/VI 100/25 mg
vs. VI 25 mg
0.029 (0.023, 0.081) 0.045 (0.008, 0.097) 0.17 (0.04, 0.38) 0.005 (0.025, 0.036)
FF/VI 100/25 mg
vs. FF 100 mg
0.168 (0.116, 0.220) 0.1 (0.047, 0.152) 0.36 (0.14, 0.57) 0.128 (0.098, 0.158)
FF 100 mg vs. PBO 0.046 (0.006, 0.098) 0.044 (0.008, 0.097) 0.12 (0.33, 0.10) 0.024 (0.006, 0.055)
Values are differences in least square mean (95% CI); FEV1 is expressed in litres; CRQ-SAS Z Chronic Respiratory Questionnaire Self-
Administered Standardized, FEV1 Z forced expiratory volume in 1 s, FF Z fluticasone furoate, PBO Z placebo, VI Z vilanterol,
wm Z weighted mean.
*p < 0.001.
**p Z 0.224.
a Peak FEV1 represents maximum post-dose FEV1 from assessments taken at 5 min, 15 min, 30 min, 1 h, 2 h and 4 h post-dose. CRQ-SAS
dyspnoea domain is scaled from 0 to 7, with 0 indicating no impairment.
Figure 3 Least squares weighted mean (0e4 h) FEV1 from
day 1 to day 168. CI Z confidence interval, FEV1 Z forced
expiratory volume in 1 s, FF Z fluticasone furoate, LS Z least
squares, VI Z vilanterol, wm Z weighted mean.
FF/VI 100/25 mg, 200/25 mg in COPD 55525 mg were typically numerically greater than those recorded
with the 200/25 mg strength of the combination (Table 2).
Results from the per-protocol population analysis (data not
shown) were consistent with those of the ITT population.
Efficacy: secondary
As an outcome of the statistical hierarchy used to analyse
results (Fig. 1), no significance can be inferred for sec-
ondary endpoints. Thus, all differences reported must be
regarded as descriptive only.
From day 1 of the study both measures of lung function
were greater (CIs not including zero) with FF/VI and VI
compared with FF and placebo. Both parameters (wm and
trough FEV1) increased rapidly from day 1 to day 14 and were
generally maintained thereafter (Figs. 3 and 4). Time-course
plots of wm FEV1 and trough FEV1 compared with placebo
and active comparator are shown in Figs. E2 and E3.
Over 6months, scores on the dyspnoea domain of the CRQ-
SAS declined relative to placebowith both strengths of FF, but
improvedwith both strengths of FF/VI andwithVI 25mg (Table
2). None of the treatment comparisons assessed achieved the
minimal clinically important difference of 0.5 units. Peak
post-dose adjusted mean FEV1 on day 1 was 120 ml in the
placebo arm, relative to baseline. In the FF 100 mg and 200 mg
arms adjustedmean peak FEV1 was 24ml (95% CI:6, 55) and
7ml (95%CI:23, 37) respectively, greater thanplacebowhile
for VI 25 mg the adjusted mean increase from placebo was
147ml (95%CI: 117, 177). Theequivalent values for FF/VI 100/
25 mg and FF/VI 200/25 mg were 152 ml (95% CI: 122, 182) and
141 ml (95% CI: 111, 171) respectively (Table 2). The time atwhich 50% of subjects (median time) achieved a 100 ml
improvement in FEV1 from baseline on day 1 was 17min for VI
25 mg, 16 min for FF/VI 100/25 mg and 17 min for FF/VI
200/25 mg. No median time could be determined for placebo
as insufficient subjects in each arm had achieved the
improvement by4 h onday 1. Serial FEV1 in all arms containing
Figure 4 Least squares mean trough FEV1, change from
baseline from day 2 to day 169. CI Z confidence interval,
FEV1 Z forced expiratory volume in 1 s, FF Z fluticasone
furoate, LS Z least squares, VI Z vilanterol.
556 F.J. Martinez et al.VI was similar during the first h post-dose on day 1; but a nu-
merical increase was apparent in the FF/VI arms on day 168
over the VI monotherapy arm (Fig. E4).
Efficacy: other
Symptomatic endpoints, as assessed by diary card and CRQ-
SAS for all treatments and comparisons are presented in
Table E1. Compared with placebo, greater improvements
(CIs excluding zero) were observed with FF/VI 100/25 mg for
all endpoints except the CRQ-SAS mastery domain. With FF/
VI 200/25 mg no difference from placebo was observed on
any domain, total score of CRQ-SAS, nor occasions of rescue
use per 24-h period; all other comparisons were greater
with FF/VI 200/25 mg compared with placebo. As per the
hierarchy of analysis, statistical significance could not be
inferred for any comparisons of ‘other’ outcomes.
Safety
No increase in the incidence of on-treatment AEs or serious
AEs (SAEs), whether drug-related or not, was observed with
active therapy vs. placebo (Table 3). Detailed summaries of
drug-related AEs, on-treatment SAEs and all AEs or SAEs
leading to withdrawal of study treatment or discontinuation
from the study are provided in Tables E2eE4. As with the
overall AE profile, no trend was observed for AEs of special
interest, related to known LABA- or ICS-mediated effects,
in the active therapy arms relative to the placebo arm
(Table 3).
Exacerbations were infrequent but occurred more often
in the placebo arm (21 events) than in any active treatment
arm and more frequently in the VI arm (18 events) than in
the FF-containing arms (14e4 events; Table E5). No pneu-
monia events were reported as an AE in the placebo arm.
With active therapy, the number of pneumonia events waslow and none of these resulted in fatality (Table E5). Chest
X-rays were conducted in 11 of the 12 subjects with pneu-
monia; of these, 10 showed infiltrates.
No clinically important abnormality was recorded for
clinical chemistry or haematology variables over the course of
the study, nor was any treatment effect observed on blood
levels of potassium or glucose. Analysis of the day 168 to
baseline ratio of UC (UC population) showed no clinical effect
of any treatment on UC excretion (Fig. E5). QTcF and ECG
heart rate were assessed post-dose on days 1 and 84 and pre-
doseondays1,84and168.Noclinical differencewasobserved
from baseline in either of these measures (Figs. E6 and E7).
A total of six deaths were reported during the study,
none of which were considered to be drug-related by the
investigator. One subject in the placebo arm died con-
sequent to myocardial infarction. Two subjects died during
VI 25 mg therapy, 1 due to anaphylaxis secondary to nuclear
stress test injection, and 1 due to accidental intoxication
with methanol. One subject each receiving FF/VI 100/25 mg
or FF/VI 200/25 mg died, due to thrombotic stroke and
myocardial infarction, respectively. One post-treatment
death was reported in a subject who received FF/VI 100/
25 mg. In that subject the cause of death is unknown;
however, the subject did have a history of congestive heart
failure coronary heart disease and hypertension.Discussion
Combination ICS/LABA therapy has been incorporated into
evidence based guidelines for the management of COPD.5e8
Relatively few data have been published regarding dose-
ranging for ICS in COPD patients.20 Furthermore, there is
now an interest in moving to once-daily dosing for respi-
ratory medications, an approach that is possible with FF/VI
therapy. To date, FF/VI has been assessed in COPD in
a small safety study,21 and in a 28-day crossover study22
while the VI component has only been assessed in one
dose-ranging study13; in all these studies significant im-
provements in lung function were observed compared with
placebo. In the novel approach presented here, the further
development of this combination therapy in COPD included
dose-ranging of the ICS component during phase IIIa stud-
ies. As such, we describe the efficacy and safety of two
strengths of FF/VI (200/25 mg and 100/25 mg) in subjects
with moderate-to-severe COPD.
This report documents (1) an improvement in wm FEV1 and
trough FEV1 with VI 25 mg compared with placebo; (2) an
improvement inwmFEV1and troughFEV1withFF/VI200/25mg
and 100/25 mg compared with placebo, for both strengths the
improvements observed were numerically greater than those
seen with VI 25 mg (3) there was no statistical difference in
trough FEV1 in change from baseline to day 169 for FF/VI
200/25mg vs. VI 25mg; (4) a rapid onsetof actionwas seen in all
VI-containing arms; and (5) no increase in on-treatment AEs,
SAEsorAEsof special interest (definedaprioriandknowntobe
related to LABA or ICS therapy) was observed with active
therapy compared with placebo. These results suggest that
once-daily therapy with FF/VI results in clinically relevant
bronchodilation in subjects with moderate-to-severe COPD
and requires further study to fully define its physiological and
clinical benefits.
Table 3 Adverse events.
n (%) Placebo
N Z 205
FF 100 mg
N Z 204
FF 200 mg
N Z 203
VI 25 mg
N Z 203
FF/VI 100/25 mg
N Z 204
FF/VI 200/25 mg
N Z 205
Summary
Any on-treatment AEs 96 (47) 78 (38) 96 (47) 85 (42) 92 (45) 93 (45)
AEs leading to permanent
discontinuation from the
study or withdrawal of
study treatmenta
23 (11) 14 (7) 15 (7) 14 (7) 20 (10) 23 (11)
Any on-treatment SAEs 10 (5) 6 (3) 10 (5) 16 (8) 12 (6) 15 (7)
Any on-treatment fatal SAEs 1 (<1) 0 0 2 (<1) 1 (<1) 1 (<1)
AEs of special interest
Cardiovascular effects 30 (15) 17 (8) 20 (10) 12 (6) 20 (10) 15 (7)
Local steroid effects 8 (4) 5 (2) 17 (8) 8 (4) 11 (5) 13 (6)
LRTI excluding pneumonia 8 (4) 7 (3) 6 (3) 5 (2) 5 (2) 2 (<1)
Effects on glucose 2 (<1) 1 (<1) 3 (1) 5 (2) 2 (<1) 3 (1)
Hypersensitivity 2 (<1) 1 (<1) 3 (1) 3 (1) 2 (<1) 2 (<1)
Pneumonia 0 2 (<1) 3 (1) 2 (<1) 1 (<1) 4 (2)
Bone disorders 0 1 (<1) 4 (2) 2 (<1) 4 (2) 0
Tremor 1 (<1) 0 0 0 1 (<1) 0
Effects on potassium 0 0 0 0 0 1 (<1)
Ocular effects 0 1 (<1) 0 0 0 0
Systemic steroid effects 0 0 0 1 (<1) 0 0
All on-treatment AEs occurring in 3% of subjects in any treatment group
Nasopharyngitis 17 (8) 14 (7) 20 (10) 19 (9) 13 (6) 13 (6)
Headache 15 (7) 13 (6) 11 (5) 20 (10) 11 (5) 15 (7)
Upper respiratory
tract infection
5 (2) 3 (1) 5 (2) 9 (4) 8 (4) 7 (3)
Oral candidiasis 2 (<1) 5 (2) 5 (2) 2 (<1) 8 (4) 4 (2)
Back pain 6 (3) 1 (<1) 2 (<1) 3 (1) 4 (2) 2 (<1)
Oropharyngeal candidiasis 3 (1) 0 7 (3) 1 (<1) 3 (1) 4 (2)
Hypertension 3 (1) 3 (1) 7 (3) 0 3 (1) 1 (<1)
AEs Z adverse events, FF Z fluticasone furoate, LRTI Z lower respiratory tract infection, SAEs Z serious adverse events,
VI Z vilanterol.
a Includes on-treatment and post-treatment.
FF/VI 100/25 mg, 200/25 mg in COPD 557We confirm that a once-daily dose of FF combined with
VI led to a sustained improvement in FEV1. These data
showed an improvement in wm FEV1 that relates predomi-
nantly to the LABA component. Importantly, trough FEV1
also improved with these three therapeutic arms in com-
parison with placebo. The lack of any statistical or clinical
difference between either of the two strengths of FF/VI
and VI suggest that any physiological improvement con-
tributed by FF was modest. This may have been further
confounded statistically in that the treatment differences
observed were smaller in magnitude than anticipated when
designing the trial, while the variability observed was larger
than that assumed in the calculation of sample size. How-
ever, it is notable that while treatment with VI alone met
the putative minimal clinically important difference from
placebo of 100 ml for trough FEV1,
23 both combination
treatments exceeded this value. Furthermore, the lack of
any clear differentiation between FF 200 mg and FF 100 mg
in terms of lung function suggests no additional benefit of
the higher dose of FF. This finding differs from the results
reported with twice-daily fluticasone propionate,2,24 and
may reflect the timing of physiological assessment, differ-
ences in the study arms, or differences in the underlyingsteroid molecule and its pharmacokinetics. Whether this
lack of demonstration of a statistically significant con-
tribution of FF to the combination on lung function effect
precludes an impact on clinically relevant outcomes such as
exacerbations remains to be determined.
We document a series of beneficial effects for the com-
bination of FF and VI with respect to patient-reported out-
comes as compared with both placebo and the combination
components. However, these results should be interpreted
with caution given the predefined statistical hierarchy for
analyses. Similarly, changes for some of these parameters
were not above the minimal clinically important difference,
suggesting that the improvements in lung function observed
did not confer a reduction in symptoms, most notably
dyspnoea. Notably a lack of a clinically important change in
the dyspnoea domain of the CRQ-SAS has also been reported
in patients with a comparable level of baseline dyspnoea
treated with fluticasone propionate/salbutamol or flutica-
sone propionate/salbutamol þ tiotropium, despite notable
improvements in lung function.25
Our data suggest there is little difference in on-treatment
AEs or SAEs with any of the active therapies compared with
placebo, at least over a 6-month comparison period. This
558 F.J. Martinez et al.conclusion also applies to assessments of events known to be
related to LABA- or ICS-mediated effects. There were
numerically fewer exacerbations in the corticosteroid-
containing regimens, with varying distribution of moderate
and severe events, although the number of events seen was
low and may be a consequence of the study entry criteria,
which did not require subjects to have a history of exacer-
bations. As such, this finding should be interpreted with cau-
tion since our study was not designed or powered to examine
the impact of FF added to VI on acute exacerbations. Addi-
tional study will be needed to better define this potential
therapeutic benefit. As in other reports of ICS in COPD,26,27
there were numerically more pneumonias reported as AEs
(none of which were fatal) in the corticosteroid containing
regimens compared with placebo, although similar numbers
were reported in the LABA alone therapeutic arm. Further
prospective data are required to define the risk of this rare
event with FF in COPD patients during longer term studies.
This was a 24-week study, a period long enough to
determine clinically meaningful bronchodilatory effects of
both the combination and its components. Additionally, it
recruited a clinically appropriate cohort of subjects and
assessed appropriate lung function endpoints. The statis-
tical hierarchy used can be regarded as both a strength and
a limitation. It is a rigorous approach for accounting for
multiplicity; however, it also limits the ability to infer
statistical significance for comparisons that fall behind the
‘point of failure’ in the hierarchy. In the present case, this
means that significance cannot be inferred for differences
of FF/VI 100/25 mg vs. its components or placebo, nor for
any comparisons of any secondary or ‘other’ endpoints.
Finally, the only symptomatic assessment conducted at the
secondary endpoint level was that of the dyspnoea domain
of the CRQ-SAS. As such, our ability to assess the impact of
adding FF to VI in terms of symptom assessment is limited.
This report confirms that the combination of FF/VI results
in a sustained improvement in FEV1 in COPD subjects with
moderate-to-severe airflow obstruction. The predominant
effect seems to come from the LABA with little effect of the
inhaledcorticosteroid, independentofdose, on lung function.
Despite this, there appeared to be modest improvements
in patient reported outcomes for the FF/VI combination
compared with its components. There were numerically
less exacerbations in the corticosteroid-treated subjects, but
interpretation of these data is limited by the small number of
exacerbations in this study population. Whether the lack of
lung function effect precludes an impact on relevant out-
comes such as exacerbations should be determined in future
studies. Overall, an evaluation of safety identified the
anticipated ICS and LABA effects. Taken together our data
suggest that a once-daily combination of FF/VI may offer an
alternative to improve lung function in COPD patients.Acknowledgements
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